NEKTAR THERAPEUTICS
NKTRUS売上高
$55M
百万USD
営業利益
$-140M
百万USD
純利益
$-164M
百万USD
ROE
-182.6%
最新FY
EPS
$-9.73
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $24M | $-123M | - |
| FY2021 | Q2 | $28M | $-126M | $-0.69 |
| FY2021 | Q3 | $25M | $-130M | $-0.70 |
| FY2021 | FY | $102M | $-524M | $-2.86 |
| FY2022 | Q1 | $25M | $-90M | $-0.49 |
| FY2022 | Q2 | $22M | $-159M | $-0.85 |
| FY2022 | Q3 | $24M | $-59M | $-0.31 |
| FY2022 | FY | $92M | $-368M | $-1.97 |
| FY2023 | Q1 | $22M | $-137M | $-0.73 |
| FY2023 | Q2 | $20M | $-51M | $-0.27 |
| FY2023 | Q3 | $24M | $-46M | $-0.24 |
| FY2023 | FY | $90M | $-276M | $-1.45 |
| FY2024 | Q1 | $22M | $-37M | $-0.19 |
| FY2024 | Q2 | $23M | $-52M | $-0.25 |
| FY2024 | Q3 | $24M | $-37M | $-0.18 |
| FY2024 | FY | $98M | $-119M | $-0.58 |
| FY2025 | Q1 | $10M | $-51M | $-0.24 |
| FY2025 | Q2 | $11M | $-42M | $-2.95 |
| FY2025 | Q3 | $12M | $-36M | $-1.87 |
| FY2025 | FY | $55M | $-164M | $-9.73 |
| FY2026 | Q1 | $11M | $-45M | $-1.82 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $1.2B | $115M | $153M | $102M | $92M | $90M | $98M | $55M |
| 営業利益 | $-113M | $-60M | $688M | $-440M | $-425M | $-446M | $-376M | $-264M | $-105M | $-140M |
| 純利益 | $-154M | $-97M | $681M | $-441M | $-444M | $-524M | $-368M | $-276M | $-119M | $-164M |
| 総資産 | $569M | $509M | $2.2B | $2.0B | $1.5B | $1.1B | $711M | $398M | $304M | $280M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $88M | $88M | $1.7B | $1.4B | $1.1B | $680M | $367M | $131M | $61M | $90M |
| 営業CF | - | - | $718M | $-329M | $-313M | $-413M | $-304M | $-193M | $-176M | $-209M |
| EPS | - | - | $3.78 | $-2.52 | $-2.49 | $-2.86 | $-1.97 | $-1.45 | $-0.58 | $-9.73 |
| BPS | $0.57 | $0.55 | $9.87 | $7.92 | $5.91 | $3.65 | $1.94 | $0.71 | $0.33 | $3.13 |
| ROE | -174.2% | -110.1% | 39.7% | -31.4% | -41.3% | -77.1% | -100.4% | -210.8% | -195.9% | -182.6% |